IRLAB Receives Notice of Allowance for U.S. Patent
IRLAB has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding a new patent directed to novel compounds for the treatment of CNS disorders. This means the patent application is to be granted. The invention is based on discoveries using IRLAB’s discovery platform, ISP, and relates to the key compounds in the P001 program.
“This is an important step in our P001 discovery program and for the pursuit of the next generation of compounds effectively treating patients suffering from motor, psychiatric and cognitive disorders. We are confident that this patent will strengthen our intellectual property portfolio, enable the selection of new drug candidates, and boost our continuing effort developing improved treatments of CNS disorders”, says Dr Clas Sonesson, IRLAB’s Chief Scientific Officer.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Clas Sonesson, CSO
Phone: +46 730 75 77 00
IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease.
IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.
IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.
IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.
For more information, please visit www.irlab.se.